Biolife Solutions INC 10-K annual reports

BioLife Solutions files an amendment to its 2025 Annual Report to provide updated disclosures regarding corporate governance, executive compensation, and director information.

BioLife Solutions, Inc. reported a 29% increase in total revenue for 2025, driven by strong demand for biopreservation media products, while continuing to streamline its portfolio through strategic divestitures and acquisitions.

BioLife Solutions has filed an amendment to its 2024 Annual Report to restate Part III, covering directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, director independence, and principal accounting fees, and to file new certifications.

BioLife Solutions' 2024 10-K filing details financial performance, strategic shifts, and risk factors, highlighting a focus on bioproduction products and services after divesting other business segments.

BioLife Solutions' 10-K filing outlines the company's share structure, voting rights, dividend policies, and anti-takeover measures, along with details on its business operations and risk factors.